175 related articles for article (PubMed ID: 19701534)
21. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
Durongpisitkul K; Gururaj VJ; Park JM; Martin CF
Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
[TBL] [Abstract][Full Text] [Related]
22. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
Yang X; Liu G; Huang Y; Chen S; Du J; Jin H
Cardiol Young; 2015 Aug; 25(6):1182-90. PubMed ID: 25597708
[TBL] [Abstract][Full Text] [Related]
24. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
[TBL] [Abstract][Full Text] [Related]
25. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
[TBL] [Abstract][Full Text] [Related]
26. [Reply to questions regarding diagnosis and treatment of Kawasaki disease].
Wang HW
Zhonghua Er Ke Za Zhi; 2006 May; 44(5):337-8. PubMed ID: 16780708
[No Abstract] [Full Text] [Related]
27. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
28. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T; Murakami S; Matsumoto K; Matsuda A
Pediatr Rheumatol Online J; 2020 Oct; 18(1):76. PubMed ID: 33023630
[TBL] [Abstract][Full Text] [Related]
29. Predicting coronary aneurysms in Kawasaki disease.
Gersony WM
Am J Cardiol; 1998 May; 81(9):1162-4. PubMed ID: 9605060
[TBL] [Abstract][Full Text] [Related]
30. Response of refractory Kawasaki disease to intravenous methylprednisolone.
Shah I; Prabhu SS
Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
[TBL] [Abstract][Full Text] [Related]
31. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
Michihata N; Matsui H; Fushimi K; Yasunaga H
Clin Pediatr (Phila); 2015 Oct; 54(11):1076-80. PubMed ID: 25573948
[TBL] [Abstract][Full Text] [Related]
32. A girl with extremely refractory Kawasaki disease: an instructive case with unusual course and outcome.
Kossiva L; Karanassios E; Papadopoulos G; Karavanaki K
Cardiol Young; 2012 Aug; 22(4):461-5. PubMed ID: 21933460
[TBL] [Abstract][Full Text] [Related]
33. Multiple giant succular and fusiform right and left coronary artery aneurysms after early and adequate treatment of atypical kawasaki disease with unusual presentation.
Behjati-Ardakani M; Ferdosian F
Acta Med Iran; 2014; 52(6):490-2. PubMed ID: 25130161
[TBL] [Abstract][Full Text] [Related]
34. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
35. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S
J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Kuwabara M; Makino N; Matsubara Y; Kosami K; Sasahara T; Belay ED
J Am Heart Assoc; 2020 Sep; 9(17):e015308. PubMed ID: 32811256
[TBL] [Abstract][Full Text] [Related]
38. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
[TBL] [Abstract][Full Text] [Related]
39. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
[TBL] [Abstract][Full Text] [Related]
40. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]